Aller au contenu principal
Fermer

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
information fournie par Boursorama CP 10/03/2021 à 17:45

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

- Enrollment of the first patient is expected in Q2 2021
- Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
- Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ("ICIs")
- Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study

.../...

Valeurs associées

1,185 EUR Euronext Paris -2,47%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.
Chargement...